CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

Capricor insiders sold shares before FDA decisions; CEO confident in data. Sellas director bought shares, gaining 430%. Iovance insiders made no trades; Q3 revenue up 80%. Institutional investors increased Sellas holdings, cut Capricor. Retail sentiment varies; IBRX up 237% YTD, CAPR down 61%.

Original reporting
Published Nov 12, 2026, 6:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 6:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge? — source image
Decision brief

The 30-second read

$CAPRBearishLow
01

Why it matters

Provides a snapshot of insider behavior but no fresh corporate disclosures; relevance is primarily informational.

02

Market read

Insider activity offers limited trading signals; investors should focus on upcoming FDA and trial outcomes.

03

What to watch

Upcoming FDA decisions and trial readouts could dominate price action more than past insider trades.

Relevance 4/10Novelty 2/10Timing: none

Background

The article aggregates recent insider trading activity and sentiment metrics for four listed biotech firms.

Company-level read

Ticker impact

$CAPRBearishMedium confidence
Context

Capricor insiders sold 1.9M shares in the quarter, reducing ownership despite 55% stake remaining.

Expected impact

potential downside as market prices in insider sales

Evidence & confidence

Large insider sell in a micro‑cap biotech often precedes weaker near‑term sentiment.

$IBRXNeutralLow confidence
Context

Institutional investors cut IBRX holdings by 1.9M shares in the quarter, though they still own 55% of the company.

Expected impact

limited impact; price may stay flat to slightly lower

Evidence & confidence

The reduction is modest relative to total holdings and no new operational news was disclosed.

$SLSBullishMedium confidence
Context

Sellas director bought 63,400 shares at $100,806 on Nov.19, 2025, a 430% paper gain ahead of REGAL trial results.

Expected impact

upward bias as market views insider buying favorably

Evidence & confidence

Director’s sizable purchase before a pivotal trial outcome often lifts sentiment.

$IOVANeutralLow confidence
Context

Iovance insiders made no trades in the past year while Amtagvi sales rose 77% to $102M, boosting Q3 revenue.

Expected impact

price likely to hold; no immediate directional catalyst

Evidence & confidence

Positive sales data exists but the article offers no new corporate event.

Market effects

Biotech sector sentiment may be modestly affected by insider activity across the four companies.

U.S. biotech micro‑caps could see slight volatility but no broad market shift.

Limited to investors tracking niche biotech equities.

Counterpoint

Insider sales may be routine portfolio rebalancing rather than a red flag.

Key entities

  • Capricor Therapeutics

    Biotech firm awaiting FDA decision for Duchenne therapy.

  • ImmunityBio

    Biotech with institutional ownership changes.

  • Sellas Life Sciences

    Biotech advancing REGAL leukemia trial.

  • Iovance Biotherapeutics

    Biotech with strong Amtagvi sales.

Related articles

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.

$SLSHighAI 9/10

Why is Sellas Life Sciences stock surging today?

Sellas Life Sciences (SLS) stock surged 245.1% in pre-market trading after its Phase 3 REGAL trial of galinpepimut-S met its primary endpoint, showing a 41% reduction in death risk. The company plans to engage with the FDA for an accelerated filing strategy. The stock was halted before resuming higher.

$SLSHighAI 9/10

SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

$SLSHighAI 9/10

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

$SLSMedAI 8/10

Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.